Study of Early Use of Dapagliflozin to Protect Heart and Kidneys in Adults with Acute Myocardial Infarction Treatment Given Before and After Primary Percutaneous Coronary Intervention

What this Trial Is About

Researchers are evaluating the early use of Dapagliflozin DAPA, a sodium-glucose cotransporter-2 SGLT2 inhibitor, in patients who have acute myocardial infarction AMI. The study aims to understand how early administration of DAPA before primary percutaneous coronary intervention pPCI affects infarct size, myocardial damage related to reperfusion injury, heart failure protection, and kidney protection from acute kidney injury. This investigation addresses the current gap in data on DAPAs effects in AMI patients, especially regarding heart failure prevention after AMI. Participants are randomly assigned to receive either Dapagliflozin 10 mg once daily or a matching placebo for three months. The treatment starts as early as possible before pPCI and continues for three months afterward. The study uses a double-blind design to compare the effects of DAPA versus placebo on heart and kidney outcomes in this patient group. Throughout the study, patients will undergo assessments including measurements of infarct size and NT-proBNP levels at three months, which relate to heart function and damage. Kidney function will also be monitored by changes in estimated glomerular filtration rate eGFR over the same period. These evaluations will help researchers understand the cardioprotective and renoprotective effects of early DAPA treatment in AMI. The total duration of participation involves treatment and follow-up assessments extending to three months.

Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI